Can interleukin-2 reverse anthracyclin chemoresistance in metastatic soft tissue sarcoma patients. Results of a prospective phase II clinical trial

European Cytokine Network

Volumn 12, Issue 2, 2001, Pages 239-243

  Gravis, G ^a   Mousseau, M ^a   Douillard, J Y ^a   Dorval, T ^a   Fabbro, M ^a   Escudier, B ^a   Mignot, L ^a   Viens, P ^a  

^a INSTITUT PAOLI CALMETTES   (France)

Author keywords

Anthracyclin; Chemoresistance; Immunotherapy; Interleukin 2; Soft tissue sarcoma

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; IFOSFAMIDE; INTERLEUKIN 2; PARACETAMOL; RECOMBINANT INTERLEUKIN 2; VINCRISTINE;

ADULT; ARTICLE; CANCER IMMUNOTHERAPY; CARDIOTOXICITY; CHEMOSENSITIVITY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; METASTASIS; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; SOFT TISSUE SARCOMA; THROMBOSIS;

ADULT; ANTIBIOTICS, ANTINEOPLASTIC; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INTERLEUKIN-2; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROSPECTIVE STUDIES; SARCOMA; TREATMENT OUTCOME;

EID: 0034982427     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: A randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
2. rIL-2 in metastatic soft tissue sarcomas refractory to chemotherapy: Response and enhancement of further chemosensitivity
3. Susceptibility of chemoresistant murine and human tumor cells to lysis by interleukin-2-activated lymphocytes
4. Treatment of chronic myelogenous leukemia with interleukin-2: A phase II study in 21 patients
5. The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapy agent
6. Immunohistochemical detection of P-glycoprotein: Prognostic correlation in soft tissue sarcoma of childhood
7. Reversal of adriamycin resistance by recombinant alpha-interferon in multidrug-resistant human colon carcinoma LoVo-doxorubicin cells
8. Combination therapy with adriamycin and interleukin-2 augments immunity against murine renal cell carcinoma
9. Augmentation of the generation of cell-mediated cytotoxicity after a single dose of adriamycin in cancer patients
10. Adriamycin-activated macrophages as tumor growth inhibitors
11. Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis
12. Combination interleukin-2 and doxorubicin in advanced adult solid tumors: Circumvention of doxorubicin resistance in soft-tissue sarcoma?